Table 3.

Tumor Response in 162 Patients with Measurable Disease

Best Overall Response	Total (N=162)
Complete response	4 (2.5%)
Partial response	69 (42.6%)
Stable disease	73 (45.1%)
≥ 24 weeks	59 (36.4%)
Progressive disease	16 (9.9%)
Objective response rate	45.1%
Clinical benefit rate	81.5%